To determine the optimal dose of acetylsalicylic acid (ASA) that would minimize both the recurrence of noncardioembolic ischemic stroke and the risk of drug-related adverse events.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
Double-blind, randomized, multicenter study.
Eligible patients will be randomized to receive 40, 80, 160, 325, 650, 975, or 1300 mg/day of ASA. They will be followed-up for two years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Recurrent stroke, MI, vascular death, serious adverse events at 2 years.|